Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics' Q1 Revenues Down 21 Percent

NEW YORK (GenomeWeb News) – Response Genetics reported after the close of the market on Thursday that its first-quarter revenues fell 21 percent and its net loss nearly doubled as it ramped up sales of its ResponseDX genetic test panels.

The Los Angeles-based firm brought in revenues of $1.5 million for the three-month period ended March 31, compared with revenues of $1.9 million for the first quarter of 2008. The firm said that the decrease was "primarily due to a delay in the receipt of clinical samples from one of our major pharmaceutical clients, which the company anticipates receiving in 2009 through 2010."

Response Genetics also said that the decline was partially offset by revenue of around $263,000 from sales of its ResponseDX: Lung and ResponseDX: Colon pharmacogenomic tests.

The firm posted a net loss of $3.3 million, or $.30 per share, up from a Q1 2008 net loss of $1.7 million, or $.17 per share.

Its R&D expenses edged up to $603,385 from $574,420 year over year, and its SG&A spending climbed to $2.5 million from $1.7 million.

Response Genetics finished the quarter with $10.2 million in cash and cash equivalents.

Filed under

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.